NEPTUNE Match Study — NEPTUNE Match  

Focal Segmental Glomerulosclerosis Clinical Trial

Official title: Nephrotic Syndrome Study Network (NEPTUNE) Match Study

Status Enrolling by invitation

Clinical Trial Summary

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

Clinical Trial Description

This is a prospective, open-label study testing the ability to effectively communicate patient-specific clinical trial matching with kidney patients and clinician investigators. The study consists of four components:

1. Recruitment of participants from the NEPTUNE observational cohort study

2. Generation of participant profile-trial match assessment using data from the NEPTUNE observational study and profiling units by the NEPTUNE Molecular Nephrology Board

3. Establishing and testing a framework to communicate disease-trial drug mechanism matching with investigators and patients

4. Retrospective comparison of kidney health outcomes in subjects enrolled in trials that aligned with their match vs. trial subjects with mis-aligned or unknown match alignment. ;

Related Conditions & MeSH terms

• Focal Segmental Glomerulosclerosis
• FSGS
• Glomerulonephritis, Membranous
• Glomerulosclerosis, Focal Segmental
• MCD
• MCD - Minimal Change Disease
• Membranous Nephropathy
• Minimal Change Disease
• Minimal Change Nephrotic Syndrome
• Nephrosis
• Nephrosis, Lipoid
• Nephrotic Syndrome
• Nephrotic Syndrome in Children
• Syndrome

• NCT number: NCT04571658
• Study type: Observational
• Source: University of Michigan
• Status: Enrolling by invitation
• Start date: March 1, 2021
• Completion date: June 30, 2026